Las flamantes diabetes tipo 3, 4 y… ¿5?

En 2008 se llegó a la conclusión de que los cerebros con alzhéimer aúnan tanto una diabetes tipo 1, como una diabetes tipo 2. Y se rebautizó a esta desgarradora demencia como la flamante «diabetes tipo 3». En 2017, el glaucoma siguió una senda similar… y se propuso como la nueva diabetes tipo 4. Y quién sabe si en un futuro cercano también el párkinson será formalmente rebautizado como la esperanzadora diabetes tipo 5.

¿Quieres oír este capítulo? Suscríbete al podcast en ivoox

y escúchalo en Apple Podcasts, Amazon Music o Spotify Podcasts.

Referencias (por orden de aparición):

De la Monte, S. M., & Wands, J. R. (2008). Alzheimer’s Disease Is Type 3 Diabetes–Evidence Reviewed. Journal of diabetes science and technology, 2(6), 1101-1113.

Daulatzai, M. A. (2017). Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer’s disease. Journal of Neuroscience Research, 95(4), 943-972.

Nigrovic, L. E., Kimia, A. A., Shah, S. S., & Neuman, M. I. (2012). Relationship between Cerebrospinal Fluid Glucose and Serum Glucose. New England Journal of Medicine, 366(6), 576-578.

Dineley, K. T., Jahrling, J. B., & Denner, L. (2014). Insulin Resistance in Alzheimer’s Disease. Neurobiology of disease, 72PA, 92-103.

Du, A. T., Schuff, N., Amend, D., Laakso, M. P., Hsu, Y., & Weiner, M. W. (2001). Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 71(4), 441.

Sterling, N. W., Lewis, M. M., Du, G., & Huang, X. (2016). Structural Imaging and Parkinson’s Disease: Moving Toward Quantitative Markers of Disease Progression. Journal of Parkinson’s Disease, 6(3), 557-567.

Tan, J., Digicaylioglu, M., Wang, S. X. J., Dresselhuis, J., Dedhar, S., & Mills, J. (2019). Insulin attenuates apoptosis in neuronal cells by an integrin-linked kinase-dependent mechanism. Heliyon, 5(8), e02294.

Watson, G. S., Peskind, E. R., Asthana, S., Purganan, K., Wait, C., Chapman, D., Schwartz, M. W., Plymate, S., & Craft, S. (2003). Insulin increases CSF Abeta42 levels in normal older adults. Neurology, 60(12), 1899-1903.

Galizzi, G., & Di Carlo, M. (2022). Insulin and Its Key Role for Mitochondrial Function/Dysfunction and Quality Control: A Shared Link between Dysmetabolism and Neurodegeneration. Biology, 11(6), 943.

Mullins, R. J., Diehl, T. C., Chia, C. W., & Kapogiannis, D. (2017). Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease. Frontiers in Aging Neuroscience, 9, 118.

Ede, G. (2019). Parkinson’s, Alzheimer’s, and the New Science of Hope | Psychology Today.

Hsieh, C.-F., Liu, C.-K., Lee, C.-T., Yu, L.-E., & Wang, J.-Y. (2019). Acute glucose fluctuation impacts microglial activity, leading to inflammatory activation or self-degradation. Nature, 9(1), 840.

Fournet, M., Bonté, F., & Desmoulière, A. (2018). Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging. Aging and Disease, 9(5), 880-900.

Kim, B., & Feldman, E. L. (2015). Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Experimental & Molecular Medicine, 47(3), e149.

Sasaki-Hamada, S., Sanai, E., Kanemaru, M., Kamanaka, G., & Oka, J.-I. (2022). Long-term exposure to high glucose induces changes in the expression of AMPA receptor subunits and glutamate transmission in primary cultured cortical neurons. Biochemical and Biophysical Research Communications, 589, 48-54.

Tomlinson, D. R., & Gardiner, N. J. (2008). Glucose neurotoxicity. Nature Reviews Neuroscience, 9(1), 36-45.

Krashia, P., Nobili, A., & D’Amelio, M. (2019). Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer’s Disease. Frontiers in Molecular Neuroscience, 12, 123.

Faiq, M. A., & Dada, T. (2017). Diabetes Type 4: A Paradigm Shift in the Understanding of Glaucoma, the Brain Specific Diabetes and the Candidature of Insulin as a Therapeutic Agent. Current Molecular Medicine, 17(1), 46-59.

Podría interesarte